Shuttle Pharmaceuticals Holdings, Inc.

SHPH

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001757499


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $10.5M
Warnings	dilution, late filer, thin data not computable: short runway, degenerate inputs, distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 31, 2026 216 days before the rescan; latest periodic filing 10-Q received Sep 24, 2026
Last close	$5.23 2026-10-30; market equity $24.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company building an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform (hereafter, "Molecule.ai" or the "platform") helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 12.1						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(34.5%)	(6.6%)	12.1	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 88.9					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(26.44)	(0.35)	78.4	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	0.06x	2.92x	99.3	829	2025-12-31
Growth and financing, sleeve percentile 68.1					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	6.6%	2.2%	38.3	696	2025-12-31
Net share issuance, one year	3,328.9%	2.5%	97.9	631	2026-03-24

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 3328.9%
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(86.4%)	(2.2%)	4
Distance from 52-week high	(83.4%)	(28.7%)	7
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(22.8%)	(1.0%)	23
Book value to price	0.78	0.28	79
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(2.16)	(0.19)	4

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$90,238
Operating cash flow, four quarters	-$6.6M
Months of runway	not finite
Days since last periodic filing	39 (10-Q received Sep 24, 2026)
Median daily dollar volume, 63 sessions	$85,784

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$11.7M	2025-12-31	2026-03-31	10-K	26-014131
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$9.5M	2025-12-31	2026-03-31	10-K	26-014131
3	assets	us-gaap:Assets	$10.5M	2025-12-31	2026-03-31	10-K	26-014131
4	assets	us-gaap:Assets	$2.5M	2024-12-31	2026-03-31	10-K	26-014131
5	current assets	us-gaap:AssetsCurrent	$502,911	2025-12-31	2026-03-31	10-K	26-014131
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.0M	2025-12-31	2026-03-31	10-K	26-014131
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$46.3M	2025-12-31	2026-03-31	10-K	26-014131
8	operating income	us-gaap:OperatingIncomeLoss	-$11.9M	2025-12-31	2026-03-31	10-K	26-014131
9	book equity	us-gaap:StockholdersEquity	$2.3M	2025-12-31	2026-03-31	10-K	26-014131
10	liabilities	us-gaap:Liabilities	$8.2M	2025-12-31	2026-03-31	10-K	26-014131
11	assets	us-gaap:Assets	$6.0M	2023-12-31	2025-02-26	10-K	25-008300
12	assets	us-gaap:Assets	$8.7M	2022-12-31	2024-09-04	10-K/A	24-034898
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	5,591,290	2026-03-24	2026-03-31	10-K	26-014131
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,076,567	2025-02-24	2025-02-26	10-K	25-008300

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.